After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...
DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 ...
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now. On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving ...
A powerful new AI tool called Diag2Diag is revolutionizing fusion research by filling in missing plasma data with synthetic yet highly detailed information. Developed by Princeton scientists and ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
Biolinq is led by CEO Rich Yang, a former manager at Dexcom and Medtronic. The company was co-founded by Chief Technology Officer Jared Tangney, who has a background in micro-array sensor research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback